Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia.

Blood Advances
Ryan D CassadayElihu Estey

Abstract

The presence of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) confers a poor prognosis. CD19-targeted immunotherapy is effective against MRD but is logistically challenging, potentially toxic, and not applicable to T-cell ALL. We thus hypothesized that inhibition of PD-1 with pembrolizumab could also be effective for MRD, but without lineage restriction. The primary objective of this phase 2 study was to evaluate the efficacy of pembrolizumab in patients with ALL and MRD. Key eligibility criteria included adults with B- or T-cell ALL and MRD detectable by multiparameter flow cytometry or quantitative polymerase chain reaction from bone marrow aspirate (BMA) despite chemotherapy (plus ABL kinase inhibitor if Philadelphia chromosome positive). Pembrolizumab 200 mg IV was given every 3 weeks. Response was assessed by BMA using methods that previously detected MRD. The primary end point was complete MRD response rate. We stopped enrollment early; only 1 of 12 (8%) experienced a complete MRD response, which lasted 3 weeks. Interestingly, this patient had previously received hematopoietic cell transplantation and CD19-targeted chimeric antigen receptor-modified T-cell therapy and was the only patient to expe...Continue Reading

References

Oct 1, 2005·Blood·Monika BrüggemannUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Oct 13, 2006·Blood·Adele K FieldingUNKNOWN Eastern Cooperative Oncology Group
Jul 15, 2016·The New England Journal of Medicine·Matthew S DavidsUNKNOWN Leukemia and Lymphoma Society Blood Cancer Research Partnership
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Dec 29, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel W LeeSattva S Neelapu
Sep 19, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S KhodadoustYoun H Kim
Oct 15, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandPier Luigi Zinzani
Nov 26, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Jae Park

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.